+202.4%
MNST vs MRNA
+554.4%
-352.0%
-27.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | +5.4% | -4.7% | +0.6% |
| 7D | -1.0% | -1.1% | +0.1% | -0.9% |
| 30D | -5.6% | +126.1% | -131.7% | -9.7% |
| 3M | -5.7% | +190.0% | -195.7% | -11.1% |
| 6M | +12.0% | +157.2% | -145.3% | +6.0% |
| YTD | +13.2% | +388.2% | -375.0% | +3.7% |
| 1Y | +36.1% | +467.0% | -431.0% | +23.4% |
| 3Y | +52.9% | +36.1% | +16.8% | +45.5% |
| 5Y | +81.0% | -68.0% | +148.9% | +78.1% |
| All | +202.4% | +554.4% | -352.0% | +150.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling